SWK Holdings Corp
NASDAQ:SWKH
SWK Holdings Corp
Cash from Investing Activities
SWK Holdings Corp
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SWK Holdings Corp
NASDAQ:SWKH
|
Cash from Investing Activities
-$10.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
LM Funding America Inc
NASDAQ:LMFA
|
Cash from Investing Activities
$7.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A-Mark Precious Metals Inc
NASDAQ:AMRK
|
Cash from Investing Activities
-$42.4m
|
CAGR 3-Years
27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-25%
|
|
|
FlexShopper Inc
NASDAQ:FPAY
|
Cash from Investing Activities
-$8.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-47%
|
|
|
California First Leasing Corp
OTC:CFNB
|
Cash from Investing Activities
-$12m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Standard Premium Finance Holdings Inc
OTC:SPFX
|
Cash from Investing Activities
-$12.3m
|
CAGR 3-Years
-482%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SWK Holdings Corp
Glance View
SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.
See Also
What is SWK Holdings Corp's Cash from Investing Activities?
Cash from Investing Activities
-10.1m
USD
Based on the financial report for Dec 31, 2024, SWK Holdings Corp's Cash from Investing Activities amounts to -10.1m USD.
What is SWK Holdings Corp's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
16%
Over the last year, the Cash from Investing Activities growth was 79%.
You don't have any saved screeners yet